What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday ...
DRUG.US股价暴涨52倍背后的秘密：Bright Minds Biosciences是如何颠覆市场的？
在近期的美股市场上，Bright Minds Biosciences（DRUG.US）以惊人的速度引起了投资者的关注。仅在五个交易日内，该公司的股价飙升了52倍，达到了历史新高。这一异动不仅令市场惊愕，也引发了各界对其背后原因的强烈探讨。那么，是什么驱动了这一股价的疯狂上涨？在这篇文章中，我们将深入分析Bright Minds Biosciences的近期动态、融资计划及其可能对市场带来的长期影响 ...
拟进行1.75亿美元非经纪人定向增发 Bright Minds Biosciences 5个交易日暴涨 ...
周五，Bright Minds Biosciences (DRUG.US)开盘再度大幅拉升，5个交易日暴涨52倍，创历史新高，截至发稿，涨超165%，报57.72美元。消息面上，公司今日宣布，将以每股21.70美元的价格 ("股票发行")进行非经纪人的普通股私募融资。除了股票发行下发行的股票外，公司保留了以每个预先资助的公司权证 (PFWs)以21.699美元每个PFW ...
Bright Minds, Firefly Neuroscience Shares Rise on Collaboration for Clinical Trial Analysis
Bright Minds Biosciences is working with Firefly Neuroscience, an AI healthcare company, to provide a full analysis of the electroencephalogram data in Bright Minds' Phase 2 clinical trial evaluating ...
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares
On October 15, 2024, Cormorant Asset Management, LP (Trades, Portfolio) made a significant move in the biotechnology sector ...
Bright Minds rally ends as psychedelic stocks extend volatility
After a nearly 15-fold rise in value in the previous session, shares of Bright Minds Biosciences (NASDAQ:DRUG) fell ~29% on ...
科莫兰特资产管理公司增持Bright Minds Biosciences Inc.股份
波士顿——作为Bright Minds Biosciences Inc. (NASDAQ:DRUG)的重要股东，科莫兰特资产管理有限合伙公司(Cormorant Asset Management, LP)通过大规模收购普通股增加了其在该公司的持股。根据最近的SEC文件显示，科莫兰特及其附属公司在截至10月16日的两天内购买了总价值约320万美元的股份。 这些交易涉及多批普通股的购买，每股价格从4.
Firefly和Bright Minds合作开发脑健康人工智能
多伦多 - 专门从事神经系统和精神疾病人工智能(AI)解决方案的Firefly Neuroscience, Inc. (NASDAQ:AIFF)宣布与Bright Minds Biosciences Inc. (CSE:DRUG) ...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN ...
Bright Minds Biosciences Shares Surge 70% on $35M Private Placement
Shares of Bright Minds Biosciences on Friday shot higher after pricing a $35 million private placement. The stock was up 70% at $36.86 in pre-market trading. The company said it has priced the private ...
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist ...
BMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in several pain ...
Nasdaq7 天
Bright Minds is Unaware of Any Material Changes
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists ...